Glioblastoma
Reference number | |
Coordinator | Uppsala universitet - Uppsala universitet Inst f kemi Ångström |
Funding from Vinnova | SEK 300 000 |
Project duration | October 2021 - March 2022 |
Status | Completed |
Venture | Preparation projects for international application within health |
Call | Preparation projects for international application within health 2021 |
Important results from the project
** Denna text är maskinöversatt ** The aim of the project was to increase the number of primary tumor types tested in animals in order to strengthen the possibility of a more effective EU proposal. The call from the EU is intended to develop multifunctional biomaterials that can be used for several applications, one of which should be highlighted as a more specific example with a business plan, scaling up, preparing GMP production and clarifying the regulatory path towards the clinic.
Expected long term effects
** Denna text är maskinöversatt ** The results were delayed and could not be used to strengthen proposal. However, the results showed / indicated that several tumor types can be treated and that more delivery routes than intravenous delivery are possible, which is very promising for the future.
Approach and implementation
** Denna text är maskinöversatt ** Production and characterization of heparin-based nanoparticles followed plan as described in proposal. Sterile lyophilized particles were delivered in time to animal studies. Glioblastoma cells were transduced with lentivirus to express Luciferase for non-invasive determination of tumor volume with IVIS camera and transplanted into the brain of mice. T15 days after transplantation of tumor into the mouse brain, the tumor in the reference group had grown so much that the experiment had to be terminated due to ethical considerations.